20 $325 Million Capital Return Program On Track to Complete Program by Year-End ~$264M completed overall; ~$61M remaining in capital return program Up to $250M of Sales-based milestones12 between 2023-2026: Long-Term Value • US royalties return after Jan. 1, 2031 MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension. | --- | --- | --- | --- | |-------|----------------------------------------------------------------|-------------------------------------------------------------------|-------| ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36033 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 98-122 ...

Progress Against 2023 Financial Targets Substantial Progress Made on Buyback Program ‣ Expanded Capital Return Program to $325M, and expect to complete by end of 2023 Co-promotion agreement with VIATRISTM (35% / 65% Profit Share) 60 $43.7 $49.1 $53.4 $55.7 $47.0 0 10 20 30 40 50 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Total YUPELRI Net Sales ($M) 1. In the US, Viatris is leading the commercialization of YUPELRI, and Theravance Biopharma co-promotes the product under a profit and loss sharing arrangement (65% to Viatr ...

Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Rick Graham - Senior Vice President of Research and Development Aziz Sawaf - Chief Financial Officer Ladies and gentlemen, good afternoon. IÂ'd like to welcome everyone to the Theravance Biopharma First Quarter 2023 Conference Call. [Operator Instructions] Also, todayÂ's conference call is being recorded. On Slide 2 IÂ'd like to remind you to that this call will contain forward-looking statements that involve risks and uncertai ...

Approved incremental $75M to existing $250M program initiated Sept'22, with goal to complete program by end of 2023 Prioritize resource allocation toward ampreloxetine Phase 3 study and YUPELRI® (revefenacin) PIFR-2 study PIFR, peak inspiratory flow rate. AGM, Annual General Meeting – May 2, 2023 ‣ Submit orphan drug designation request in early 2023 ‣ $50M potential milestone for TRELEGY Net Sales of ~$2.86B2 Co-promotion agreement with VIATRISTM (35% / 65% Profit Share) Net sales increased 27% Q4'22 vs. Q ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36033 THERAVANCE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Cayman Islands 98-1226628 (Sta ...

Rick Winningham - Chairman and Chief Executive Officer Rhonda Farnum - Senior Vice President, Chief Business Officer Rick Graham - Senior Vice President, Research and Development Aziz Sawaf - Chief Financial Officer Theravance Biopharma Inc. (NASDAQ:TBPH) Q4 2022 Results Conference Call February 27, 2023 5:00 PM ET Company Participants Conference Call Participants David Risinger - SVB Securities Douglas Tsao - H.C. Wainwright Eva Privitera - Cowen Vikram Purohit - Morgan Stanley Liisa Bayko - Evercore ISI O ...

| --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | | | | Third Quarter 2022 Financial Results and Business Update | | | November 7, 2022 | | | THERAVANCE BIOPHAR ...

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Rick Winningham – Chairman and Chief Executive Officer Rhonda Farnum – Senior Vice President, Chief Business Officer Rick Graham – Senior Vice President, Research and Development Andrew Hindman – Chief Financial Officer Conference Call Participants Eva Privitera – Cowen Douglas Tsao – H.C. Wainwright Joseph Stringer – Needham Brian Skorney – Baird David Risinger – SVB Securities Operato ...

| --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | | | | Transformed and Focused on Medicines that Make a Difference | | | September 13, 2022 | | | THERAVANCE BI ...